Agree.........I find it interesting that Roche has yet to make public the durability of response for all the responders in that trial. If the responses were durable, then I think the FDA would be hard pressed to RTF (unless there was a high percentage of missing scans or some other data management issues).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.